Celebrating our 10th anniversary – Unlock our special offer today

Cann Group teams up with Emyria to develop pharmacy grade CBD capsules

Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria
Read full article
I'm already a subscriber
Author default picture

Lorraine Mullaney

Senior writer
Lorraine is responsible for writing news analysis and assisting with copy-editing. Lorraine is a copywriter and editor who has written and edited words for a wide range of audiences, from local community newspapers to consumer magazines and trade websites.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization